Ethernet Alliance points to 800GbE, 1.6TbE

New Post Public Reply Private Reply Replies (0) Message Board
proto
576
Ethernet Alliance points to 800GbE, 1.6TbE future

standards exist for 2.5Gb/s, 5Gb/s, 25Gb/s, 40Gb/s, 50Gb/s, 100Gb/s, 200Gb/s, and 400Gb/s.

The latter is currently where Ethernet hits its limit, but the Ethernet Alliance - a consortium of companies currently responsible for developing the eponymous networking standard - is preparing 800GbE, which as the name implies offers 800Gb/s throughput, while suggesting that 1.6TbE could launch alongside it or shortly after.


'Ethernet is bursting through speed barriers at a breakneck pace. With higher speeds and longer reaches, it’s now pushing past its history as an innovative consumer technology into diverse new markets and application spaces like enterprise storage, automotive, and building automation,' claims Greg McSorley, president of the Ethernet Alliance, following the development of demonstrations scheduled for the European Conference on Optical Communications (ECOC 2019) later this month. 'The 400GbE era is here but it’s only a stepping stone along the road to 800GbE. The secret to Ethernet’s continued success has always been and will continue to be interoperability. Getting traffic to travel seamlessly from today’s legacy implementations into tomorrow’s high-speed switches and ecosystems comes down to preserving Ethernet’s capacity for multi-vendor interoperability, which is highlighted in our ECOC 2019 demo.'

The Alliance, however, is somewhat quiet on exactly when the 800GbE and 1.6TbE standards are likely to be ratified: The public roadmap has them pushed projected for around 2022 or later - though only as 'possible future speed' rather than a fully-confirmed theoretical throughput limit - which has been its target since unveiling its plans back in March 2018.


https://www.bit-tech.net/news/tech/networking...-future/1/

Ok, so only LWLG can get to 400Gbs with 4 lanes NRZ OOK, this is the ONLY cheap, simple solution to 400Gbs, all of the other Legacy technologies can get there by using PAM4 and 50Gbs devices, but only LWLG can deliver 100Gbs devices that can achieve 400Gbs transmissions WITHOUT complex, expensive modulation formats

LWLG is currently in FINAL optimizations of a 100Gb PkM Gen2 2.5V device which is TWICE the speed and HALF the power of all the Legacies! LWLG will soon be unveiling this device with Power reduced to sub-1V and this is truly the holy grail of Photonics as it will eliminate the need for a power hungry "Driver" for the modulator to function, instead LWLG's device being so low voltage it will power directly from the CMOS itself without a driver!

when you get to 800Gbs it gets even tougher for the Legacies, they would now need to increase to 8 lanes at their max speed 50Gbs and use PAM4, with LWLG you could still stay at 4 lanes with 100Gbs devices but require PAM4, however LWLG has already demonstrated device speeds as high as 130GHz which translates to 150Gbs standalone device speeds, so investors know that already an optimized version of the 150Gbs device would support 600Gbs NRZ, simple and cheap, but investors also already know that LWLG's technology has PROVEN femtosecond response times which in theory means LWLG's technology can get to 1Tb standalone speeds (that's 1,000Gb!) meaning that it is possible to extend LWLG's simple and cheap NRZ OOK to support 4Tb (4,000Gb) transmissions using 4 lanes running at 1Tb NRZ OOK, this is simply off the charts incredible!

Lightwave Logic Inc (LWLG) Stock Research Links

LWLG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 21

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Morgan Stanley Projects Strong Upswing for Consumer Finance

Updated Category News Views 259

Morgan Stanley's Positive Outlook for Consumer Finance Stocks Morgan Stanley has recently made an uplifting adjustment to its outlook on consumer finance stocks, now branding them as "attractive." This decision stems from robust fundamentals and an improved regulatory environment, setting an optimistic tone for the sector. Key Drivers of Change The primary catalysts...

Continue Reading
Significant Board Restructuring at O2Gold Inc. Announced

Updated Category News Views 71

O2Gold Board Announces Key Changes O2Gold Inc. (NEX: OTGO.H), a dedicated mineral exploration company, has recently undergone a significant change in its board structure. The company has announced that Roger Lemaitre has resigned from his position as a director. This decision marks a pivotal moment for O2Gold as it continues to navigate its exploration initiatives....

Continue Reading
Taylor Morrison Launches Holiday Initiative to Support Homeowners

Updated Category News Views 265

Help for Homeowners During the Holidays In a time when financial strain can be prominent, especially during the holidays, Taylor Morrison (NYSE: TMHC) is stepping up to lend a hand. The renowned homebuilder has introduced an initiative designed to support homeowners facing the threat of foreclosure. With the holiday season often heightening financial challenges, the...

Continue Reading
flatexDEGIRO Moves Ahead After Ending BaFin Oversight

Updated Category News Views 188

flatexDEGIRO Ends Special Commissioner Mandate FRANKFURT - flatexDEGIRO AG, a prominent German financial services provider, has officially announced the conclusion of the special commissioner mandate set by the Federal Financial Supervisory Authority (BaFin). This change will take effect on a specified date in the future. The company has made significant strides in...

Continue Reading
Investigating Alvotech's Regulatory Challenges After Stock Drop

Updated Category News Views 125

Alvotech Faces Scrutiny over Manufacturing Issues National shareholder rights firm Hagens Berman is currently analyzing Alvotech (NASDAQ: ALVO) regarding potential misrepresentations in their disclosures tied to manufacturing operations and the regulatory status of their primary biosimilar candidate, AVT05. Impact of FDA's Complete Response Letter The investigation stems...

Continue Reading